Paolo Bossi
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)

Paolo Bossi

ASST Spedali Civili Di Brescia
Brescia, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
ASST Spedali Civili Di Brescia
Brescia, IT 
OverviewLocationsClinical Research

Overview

Paolo Bossi practices in Brescia, Italy. Mr. Bossi is rated as an Elite expert by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma, Adenoid Cystic Carcinoma, Laryngectomy, and Endoscopy.

His clinical research consists of co-authoring 398 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 76 articles and participated in 2 clinical trials in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Gender
Male

Locations

ASST Spedali Civili di Brescia
Brescia, Italy
Other Locations
Unit Of Otorhinolaryngology Head And Neck Surgery, Brescia, 25123, Italy
Bg, Treviglio, 24047, Italy
Head And Neck Medical Oncology Unit, Milan, 20133, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab, Fluorouracil, Cisplatin, Carboplatin
Study Phase: Phase 3
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
Preemptive Treatment With XONRID a Medical Device to Reduce Radiation Induced Dermatitis in Head and Neck Cancer Patients Receiving Curative Treatment
Preemptive Treatment With XONRID a Medical Device to Reduce Radiation Induced Dermatitis in Head and Neck Cancer Patients Receiving Curative Treatment
Enrollment Status: Completed
Publish Date: September 29, 2021
Intervention Type: Device
Study Phase: Not Applicable
Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract
Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract
Enrollment Status: Completed
Publish Date: September 03, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract
Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract
Enrollment Status: Completed
Publish Date: August 30, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

398 Total Publications

PD-L1 Expression in head and neck squamous cell carcinoma: qualitative or quantitative assessment? Is that enough or we need something more?
PD-L1 Expression in head and neck squamous cell carcinoma: qualitative or quantitative assessment? Is that enough or we need something more?
Journal: Oral oncology
Published: August 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bossi's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 40 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile